T 0592/24 (Cancer combination therapy/NOVARTIS) of 13.04.2026
- European Case Law Identifier
- ECLI:EP:BA:2026:T059224.20260413
- Date of decision
- 13 April 2026
- Case number
- T 0592/24
- Online on
- 2 June 2026
- Petition for review of
- -
- Application number
- 14752433.4
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- COMBINATION THERAPY FOR THE TREATMENT OF CANCER
- Applicant name
- Novartis AG
- Opponent name
- TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Stada-Arzneimittel Aktiengesellschaft
Generics [UK] Limited
Hoffmann Eitle Patent- und Rechtsanwälte
Partnerschaftsgesellschaft mbB
Bachelin, Martin - Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 123(2)European Patent Convention Art 83European Patent Convention Art 56Rules of procedure of the Boards of Appeal 2020 Art 012(4)Rules of procedure of the Boards of Appeal 2020 Art 013(1)Rules of procedure of the Boards of Appeal 2020 Art 013(2)
- Keywords
- Amendments - added subject-matter (no)
Sufficiency of disclosure - (yes)
Inventive step - (yes)
Inventive step - unexpected improvement shown
Inventive step - closest prior art
Inventive step - try-and-see situation (no)
Amendment to case - amendment admitted (no)
Amendment to appeal case - amendments admitted (no) - Catchword
- -
- Cited cases
- G 0002/21T 0686/91T 0512/02T 0484/09T 0405/14T 0419/16T 1989/19T 0314/20T 0887/21T 0840/22T 1994/22T 0722/24
- Citing cases
- -
Order
For these reasons it is decided that:
The appeals are dismissed.